1. Legha S, Ajani JA, Bodey GP. Phase 1 study of spirogermanium given daily. J Clin Oncol 1983; 1: 331–35.
2. Kavanagh JJ, Saul PB, Copeland LJ, Gershenson DM, Krakoff IH. Continuous-infusion spirogermanium for the treatment of refractory carcinoma of the ovary: a phase 2 trial. Cancer Treat Rep 1985; 69: 139–40.
3. Woolley PV, Ahlgren JD, Byrne PJ, Priego VM, Schein PS. A phase 1 trial of spirogermanium administered on a continuous infusion schedule. Invest New Drugs 1984; 2: 305–309.
4. Pinnamaneni K, Yap HY, Legha SS, Blemenschein GR, Bodey GP. Phase 2 study of spirogermanium in the treatment of metastatic breast cancer. Cancer Treat Rep 1984; 68: 1197–98.
5. Warrell RP Jr., Coonley CJ, and Gee TS. Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia. J Clin Oncol 1985; 3: 617–21.